Cargando…

Ectopic Overexpression of PPARγ2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of Diabetes

The clinical controversy of rosiglitazone as a hypoglycemic agent is potentially associated with heart failure, mainly due to its potent activation of peroxisome proliferator-activated receptor γ (PPARγ). PPARγ partial agonists showed superior pharmacological profiles to rosiglitazone. This study co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Xuemei, Mao, Min, Diao, Junlin, Hou, Yi, Su, Hong, Gan, Yongjun, Li, Jibin, Tong, Xiaoyong, Wu, Chaodong, Zuo, Zhong, Xiao, Xiaoqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293689/ https://www.ncbi.nlm.nih.gov/pubmed/34305596 http://dx.doi.org/10.3389/fphar.2021.683156

Ejemplares similares

Thiazolidinediones on PPARγ: The Roles in Bone Remodeling
por: Wei, Wei, et al.
Publicado: (2011)

Deciphering the Roles of Thiazolidinediones and PPARγ in Bladder Cancer
por: Chiu, Melody, et al.
Publicado: (2017)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

CMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss
por: Hou, Yi, et al.
Publicado: (2018)

Brain PPARγ Promotes Obesity and is Required for the Insulin–Sensitizing Effect of Thiazolidinediones
por: Lu, Min, et al.
Publicado: (2011)

PPARγ-Independent Side Effects of Thiazolidinediones on Mitochondrial Redox State in Rat Isolated Hearts
por: Riess, Matthias L., et al.
Publicado: (2020)

Insulin Sensitizing Pharmacology of Thiazolidinediones Correlates with Mitochondrial Gene Expression rather than Activation of PPARγ
por: Bolten, Charles W., et al.
Publicado: (2007)

Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
por: Yasmin, Sabina, et al.
Publicado: (2017)

PPARγ activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFβ signalling
por: Jarrar, Mohammed H, et al.
Publicado: (2007)

Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists
por: Najmi, Asim, et al.
Publicado: (2023)

Neonatal overfeeding in mice aggravates the development of methionine and choline-deficient diet-induced steatohepatitis in adulthood
por: Du, Juan, et al.
Publicado: (2018)

Hypertrophic Cardiomyopathy and Primary Restrictive Cardiomyopathy: Similarities, Differences and Phenocopies
por: Vio, Riccardo, et al.
Publicado: (2021)

Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?
por: Jaafar, Nawel, et al.
Publicado: (2015)

Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy
por: Parato, Vito Maurizio, et al.
Publicado: (2016)

Sex differences in the prognosis of patients with hypertrophic cardiomyopathy
por: Kim, Minkwan, et al.
Publicado: (2021)

PPARγ attenuates hypoxia-induced hypertrophic transcriptional pathways in the heart
por: Chaudhry, Abubakr, et al.
Publicado: (2017)

Sex, Survival, and Cardiomyopathy: Differences Between Men and Women With Hypertrophic Cardiomyopathy
por: Siontis, Konstantinos C., et al.
Publicado: (2019)

Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy
por: Puckelwartz, Megan J., et al.
Publicado: (2021)

Specific Thiazolidinediones Inhibit Ovarian Cancer Cell Line Proliferation and Cause Cell Cycle Arrest in a PPARγ Independent Manner
por: Al-Alem, Linah, et al.
Publicado: (2011)

Periostin is overexpressed, correlated with fibrosis and differs among grades of cardiomyocyte hypertrophy in myectomy tissue of patients with hypertrophic cardiomyopathy
por: Ioakeimidis, Nikolaos S., et al.
Publicado: (2023)

Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment
por: Butters, Alexandra, et al.
Publicado: (2021)

Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
por: Vakrou, Styliani, et al.
Publicado: (2021)

Differing strategies for sudden death prevention in hypertrophic cardiomyopathy
por: Maron, Martin S, et al.
Publicado: (2023)

Echocardiography Differences Between Athlete’s Heart Hearth and Hypertrophic Cardiomyopathy
por: Kreso, Amir, et al.
Publicado: (2015)

Age-related sex differences in the outcomes of patients with hypertrophic cardiomyopathy
por: Lee, Hyun-Jung, et al.
Publicado: (2022)

Hypertrophic cardiomyopathy
por: Antunes, Murillo de Oliveira, et al.
Publicado: (2020)

Hypertrophic Cardiomyopathy
por: Butt, Asra K., et al.
Publicado: (2023)

Multi-factor regulatory network and different clusters in hypertrophic obstructive cardiomyopathy
por: Qin, Xianyu, et al.
Publicado: (2021)

PPARγ Controls Ectopic Adipogenesis and Cross-Talks with Myogenesis During Skeletal Muscle Regeneration
por: Dammone, Gabriele, et al.
Publicado: (2018)

Ghrelin Alleviates Experimental Ulcerative Colitis in Old Mice and Modulates Colonocyte Metabolism via PPARγ Pathway
por: Muthyala, Srilakshmi, et al.
Publicado: (2022)

Molecular Mechanism of Thiazolidinedione-Mediated Inhibitory Effects on Osteoclastogenesis
por: Zhao, Dongfeng, et al.
Publicado: (2014)

Sex-Related Differences in Protein Expression in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Hypertrophic cardiomyopathy surgery: Perioperative anesthetic management with two different and combined techniques
por: Bellas, José J. Arcas, et al.
Publicado: (2021)

Different Phenotypes in Monozygotic Twins, Carriers of the Same Pathogenic Variant for Hypertrophic Cardiomyopathy
por: Rodríguez Junquera, Manuel, et al.
Publicado: (2022)

The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy
por: Kittleson, Mark D, et al.
Publicado: (2021)

Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver
por: Ebihara, Chihiro, et al.
Publicado: (2022)

Hypertrophic Obstructive Cardiomyopathy
por: Cohen, Lawrence S.
Publicado: (1972)

The genetics of hypertrophic cardiomyopathy
por: Akhtar, Mohammed, et al.
Publicado: (2018)

Disopyramide for Hypertrophic Cardiomyopathy
por: Sanchez-Nadales, Alejandro, et al.
Publicado: (2019)

Chemotherapy and Chemoprevention by Thiazolidinediones
por: Fröhlich, Eleonore, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gmnqhemutctitrsjveb4oo9o04